We tested our antibodies against ESRP1 and ESRP2 proteins on prostate cancer FFPE tissue and cell blocks, but they did not pass our stringent quality control tests (Figure 1—figure supplement 1C). While this manuscript was in preparation, another group used an alternative ESRP1 antibody to show up-regulation of ESRP1 in 12,000 prostate cancer tissue microarray tumours (Gerhauser et al., 2018). This evidence concerns the gene ESRP2 and neoplasm.